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RatAbstract This study was performed for evaluation of the effect of pre-operative and post-operative
administration of tramadol and meloxicam combination on hyperalgesia and selected inﬂammatory
responses after sciatic nerve ligation in rats. An eighty male Wistar rats (Rattus norvegicus) were
divided into two groups; preemptive analgesic group, in which the rats received analgesic agents
30 min before nerve ligation. Also the nociceptive pain tests were detected before surgery, 120
and 150 min post-analgesics injection. The serum IL-6 and PGE-2 concentrations were detected
at 150 min post-analgesics injection. The second group was post-operative analgesic group; in which
the rats exposed for the nerve ligation then the rats received analgesic agents at 5 till 11 day’s
post-operative. Behavioral tests were performed before surgery and on each even days post-
operatively. The serum concentration of IL-6 and PGE-2 was determined at 5, 10 and 14 days
post-operative. Tramadol and meloxicam combination had a statistically signiﬁcant (P< 0.05)
reverse hyperalgesia while preemptive administration of tramadol and meloxicam signiﬁcantly
decreased (P< 0.05) serum IL-6 production compared to post-operative treatment. In conclusion,
the preemptive combination of tramadol and meloxicam produced a potent analgesic effect post
nerve ligation in rats.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Veterinary Medicine, Cairo
University.1. Introduction
Nerve injury often results in development of hyperalgesia char-
acterized by spontaneous pain, increased responsiveness to
painful stimuli and allodynia which is a pain perceived in
response to normally non-noxious stimuli [1,2]. Chronic
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condition for which there is no adequate treatment to prevent
the development predictably and speciﬁcally controls estab-
lished neuropathic pain [3]. Insults to the central and periphe-
ral nervous system can range from traumatic injury to
chemical insult and to immunologic challenge [3,4].
Pains evoked from tissue destruction as well as during
wound healing, inﬂammatory reaction are elicited this leads
to activation of nociceptors (pain receptors) which can
cross-communicate with the inﬂammatory inﬁltrate [2,3].
Among cytokines involved in pathological states, an impor-
tant role is assigned to interleukin-6 (IL-6); an inﬂammatory
cytokine, involved in the physiology of nociception and the
pathophysiology of pain [5,6]. Prostaglandin E2 (PGE-2) is
a key mediator in the processes of peripheral and spinal sen-
sitization [7,8].
Cytokines activation take place following a neuroma
formation after axotomy and increases neuronal activity and
hyperalgesia when administered spinally [9,10]. Research using
rat models has mainly focused on injury to a peripheral nerve,
usually the sciatic or spinal nerve, to consistently produce
behaviors suggestive to neuropathic pain in humans [11–13].
The choices of a drug modulating the immune responses are
beneﬁcial in the peri-operative period [14]. It has been demon-
strated that tramadol can contribute to beneﬁcial effects on
immune functions in patients, namely, induce an improvement
of post-operative immunosuppression [15].
Meloxicam is a novel non-steroidal anti-inﬂammatory drug
(NSAID) and cyclooxygenase COX-2 inhibitor. It has been
shown to have a potent anti-inﬂammatory effect in rats at
doses that only weakly affect prostaglandin synthesis in the
stomach and kidneys [16]. Tramadol is a synthetic, centrally
acting, analgesic agent with opioid and non-opioid like proper-
ties [18]. Its analgesic effect in experimental pain models in rats
was shown in thermal hyperalgesia [19]. It could be an effective
and dose-dependent control for heat hyperalgesia in chronic
nerve constriction injury in rats [20].
The combination of tramadol and meloxicam has the po-
tential to overcome tolerance, efﬁcacy and time-to-onset limi-
tations of the component drugs and increase their analgesic
effect synergistically [14]. Thus the aim of the current study
was to evaluate the effect of pre- and post-treatment with
tramadol and meloxicam combination on pain anti-nocicep-
tive test (thermal pain tests) and its effect on serum level of
IL-6 and PGE-2 in rats undergoing sciatic nerve constriction
injury.
2. Materials and methods
2.1. Animals and housing
Eighty apparently healthy male Wistar rats (Rattus norvegicus)
(aged 2–3 years; average body weight, 250–300 g) were used.
Rats were housed under standard laboratory conditions (tem-
perature: 23 ± 2 C, with a 12-h/12-h light/dark cycle). They
had free access to standard laboratory feed and water up to
the time of the experiment. All experiments were conducted
in accordance with the Guidelines on Ethical Standards for
Investigation of Experimental Pain in Animals [21]. In addi-
tion, the protocol was approved by the Mansoura Medical Re-
search Ethics Committee (MMREC).Tramadol hydrochloride (15 mg/kg; Tramal 5%, Minp-
harm, Gru¨nenthal, Germany; T15), meloxicam, (6 mg/kg;
Anti-CoxII 0.5%, Adwia, Cairo, Egypt; M6), medetomidine
hydrochloride (0.4 mg/kg; Domitor 0.1%, Pﬁzer, Seixal, Por-
tugal) and ketamine hydrochloride (60 mg/kg; Ketamax 5%,
Troikaa, Gujarat, India).
2.2. Experimental procedure and treatments
Rats had randomly assigned into two main groups; preemptive
group: which include preemptive T15, M6, T15 +M6 or sal-
ine (5 rats for each treatment) and post-operative group: which
include post-operative T15, M6, T15 +M6 or saline (15 rats
for each treatment).
The rats were received 1 ml saline IM in control group or
T15, M6 or combination between each other at 30 min before
injection of anesthetics in preemptive groups while in post-
operative groups they received the same drugs from the 5th till
11th days post-operative.
In the preemptive analgesic treatment, thermal pain tests
were assessed before surgery (base line) and 120 and 150 min
post-injection of analgesics, whereas in the post-operative
analgesic groups, thermal pain tests were assessed at base line
then at 2, 4, 6, 8, 10, 12 and 14 days post-operatively.
2.3. Neuropathic pain (sciatic nerve ligation)
The model of sciatic nerve injury was performed at the mid-
thigh level of the left hind leg [22]. Brieﬂy, animals were anes-
thetized with combination of medetomidine hydrochloride and
ketamine hydrochloride intra-peritoneum and the surgery were
aseptically performed. One sterile chromic gut suture (4-0
chromic gut, Ethicon, USA) was loosely ligated around the
gently isolated sciatic nerve proximal to its trifurcation. The
muscles overlying the nerve were sutured with chromic gut lig-
ature (3-0) (Sharpoint, USA).
2.4. Thermal pain latency tests [12]
2.4.1. Tail withdrawal latency test (TWL)
The water was maintained at 50 C in a constant-temperature
water bath. Rats were wrapped in a breathable cloth cone, and
the distal third of the rat’s tail was immersed in the bath. The
time required for the rat to remove its tail was measured by use
of a stopwatch, and the tail-ﬂick latency score was calculated
as the mean of the last 2 of 3 trials. Trials were separated by
30 s intervals. Between trials, the rat’s tail was dried with a tis-
sue (one swipe beginning at the mid-tail region) and was termi-
nated at 30 s if no withdrawal response occurred.
2.4.2. Hot plate test
All animals were placed on a hot plate apparatus maintained
at a temperature of 50 C. The anti-nociceptive effect was
quantiﬁed by measuring latency times for kicking, licking of
hind paw or jumping. Each rat had just been exposed to the
hot plate before analgesic drug injection and after 30 and
60 min. The time required for the rat was measured by use
of a stopwatch, and the latency times were calculated as the
mean of the last 2 of 3 trials. A cut off time of 15 s was consid-
ered if no response.
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Rats were quickly decapitated to collect trunk blood for
assessment of serum IL-6 and PGE-2 level. Blood samples
were centrifuged at 3000 rpm for 10 min, and the separated
sera were stored at 80 C until being used in the assay. Serum
PGE-2 was detected by using Rat PGE-2 commercial ELISA
kits (Pierce, USA) and serum interleukin-6 by using Rat IL-6
ELISA kit (Pierce, USA) at 2 h post-operatively in preemptive
group and at 5, 10 and 14 days in post-operative group.
2.6. Statistical analysis
Data were analyzed using one-way ANOVA showed signiﬁ-
cant differences among groups. Analysis was performed with
the software SPSS version 16.0 (SPSS Inc, USA). To determine
which groups are different, the data were analyzed by Dun-
nett’s test was used to compare the experimental groups versus
respective saline treatment using Statistical program. The data
in thermal pain tests after surgical experiment were expressed
as mean of TWL (second) ± stander deviation. While in bio-
chemical analysis data were presented as mean of production
of IL-6 (pg/ml), PGE-2 (pg/ml) ± stander deviation.
3. Results
Prior to nerve ligation, thermal withdrawal latency showed no
signiﬁcant difference in all rats in both acute preemptive and
chronic post-operative treatments.
3.1. Acute preemptive group
In this group, rats treated with normal saline exhibited little in-
crease of TWL after 120 and 150 min post-treatment compared
to base line while T15 mg/kg induced a signiﬁcant decrease
(P< 0.05) heat hyperalgesia in thermal pain tests post analge-
sic injection compared to M 6 mg/kg and saline one. The
administration of M6 mg/kg showed a mild signiﬁcant increase
of WLT post analgesic injection compared to saline. On the
other hand, the rats which were treated with T15 +M6 showed
statistical signiﬁcance decreased (P< 0.05) of thermal hyperal-
gesia and increased of withdrawal latency time (Table 1).
An acute preemptive anti-nociceptive effect of (tramadol
15 mg/kg plus meloxicam 6 mg/kg) in sciatic nerve injury
was accompanied by a smooth anesthetic induction, short
induction of anesthesia and prolong recovery period.Table 1 Mean values ± standard error of withdrawal latency (s) of
test) baseline and after 120 and 150 min from preemptive acute anal
Treatments Hot plate test (s)
Baseline 120 min 150 min
Saline 11 ± 0.7a 13.8 ± 1c 12.4 ± 1b
M6 11 ± 0.7a 14.5 ± 1cb 13.8 ± 1.
T15 11 ± 0.7a 21.4 ± 1.8b 20.6 ± 0.
T15 +M6 11 ± 0.7a 24.8 ± 1.4a 22.8 ± 1.
Means with different superscript letters at the same column are signiﬁcan
M6: meloxicam (6 mg/kg).
T15: tramadol (15 mg/kg).
T15 +M6: tramadol (15 mg/kg) and meloxicam (6 mg/kg) combination.3.2. Chronic post-operative group
In this group, thermal hyperalgesia was detected 2 days
post-operative and noticed 4 days post-operative as well as de-
creased withdrawal latency time of thermal tests compared to
base line (Fig. 1).
In control group thermal hyperalgesia appeared at day 4 post-
operative and reached to maximum value at 8 day following the
surgery and then ﬂuctuated in the second week after operation.
Chronic post-operative intramuscular injection of analgesic
drugs (T15 mg/kg, M6 mg/kg or T15 mg/kg +M6 mg/kg)
showed signiﬁcant decrease (P< 0.05) of thermal hyperalgesia
post-injection. This was indicated by increase of TWL com-
pared to saline (Fig. 1).
Chronic post-operative administration of T15 mg/kg post-
injection induced a signiﬁcant reduction (P< 0.05) of thermal
hyperalgesia when compared to the saline one at 6, 8, 10 and
12 days post-operative. The highest TWL index in T15 mg/kg
treatment was reached at day 10 post-operative and was signif-
icantly different (P< 0.05) from the pre-operative baseline
value (Fig. 1).
Post-operative chronic injection of M6 mg/kg into operated
rats produced a partial relief of thermal hyperalgesia compared
to saline injected operated rats at day 6, 8, and 10 post-opera-
tive. Whereas, at day 12 and 14 post-operative, thermal hyper-
algesia was rebound and showed no difference between saline-
treated rats and rats treated with a meloxicam.
The combination of 15 mg/kg dose of tramadol and
6 mg/kg of meloxicam, in chronic post-operative injection, was
completely reverse neurologic inﬂammatory thermal hyperalge-
sia, and produced a signiﬁcantly higher (P< 0.05) thermal
withdrawal latency compared to control group. At 12 and
14 days post-operative, the withdrawal latency time had
signiﬁcant differences (P< 0.05) than saline injected rats.3.3. Biochemical analysis
3.3.1. In acute preemptive group
Serum IL-6 levels were signiﬁcantly increased (P< 0.05) at 2 h
after nerve injury in saline one (Table 2). T15 mg/kg +M6 mg/
kg had a minimal signiﬁcant decrease (P< 0.05) of the serum
IL-6 after 2 h post nerve injury compared to other treatments.
In T15 mg/kg treatment, the IL-6 showed signiﬁcant decrease
(P< 0.05) compared to M6 mg/kg and saline one (Table 2).
Serum PGE-2 level remained unchanged in rats which
received saline but in rats received T15 mg/kg showed a littleanti-nociceptive tests (tail withdrawal latency test and hot plate
gesic groups in albino rats.
Tail withdrawal latency (s)
Baseline 120 min 150 min
4.6 ± 0.3a 5.4 ± 0.5c 4.6 ± 0.2c
2cb 4.6 ± 0.2a 6.5 ± 0.6cb 6.8 ± 0.4cb
4b 4.6 ± 0.7a 10.6 ± 0.5b 9.2 ± 0.3b
5a 4.6 ± 0.1a 12.2 ± 0.7a 12.4 ± 0.6a
tly different at P< 0.05.
Figure 1 Mean curves depicting the withdrawal latency time (s) of anti-nociceptive tests in albino rats before operation and at days 2, 4,
6, 8, 10, 12 and 14 post-operative after administration of 1 ml/kg saline or tramadol 15 mg/kg and 6 mg/kg of meloxicam. (A) Hot plate
test. (B) Tail withdrawal latency test.
Table 2 Mean values ± standard error of serum IL-6 (pg/ml)
and PGE-2 (pg/ml) level 2 h post-operation in preemptive acute
analgesics group.
Treatment IL-6 (pg/ml) PGE-2(pg/ml)
Saline 967.8 ± 2.6a 3750 ± 23.6a
M6 271 ± 12.01b 2368.4 ± 3.8b
T15 170.4 ± 3.7c 2767.8 ± 9.2ab
T15 +M6 109.2 ± 1.8d 2347.8 ± 2.5b
Means with different superscript letters at the same column are
signiﬁcantly different at P< 0.05.
M6: meloxicam (6 mg/kg).
T15: tramadol (15 mg/kg).
T15 +M6: tramadol (15 mg/kg) and meloxicam (6 mg/kg)
combination.
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ment. In M6 mg/kg treatment, it was reduced signiﬁcantly
(P< 0.05) than saline and T15 mg/kg. On the other hand,
T15 mg/kg +M6 mg/kg treatment had a maximum reduction
of serum PGE-2 than saline, T15 mg/kg or M6 mg/kg alone
after 2 h post nerve injury (Table 2).3.3.2. In chronic post-operative group
On 5th day post-operation, the serum IL-6 and PGE-2
post-operation had no signiﬁcant difference between different
treatments. Whereas on 10 and 14 days post-operation, the
serum IL-6 signiﬁcant increase (P< 0.05) in both treated rats
and control group. Further, in post-operative treatment with
M6 mg/kg plus T15 mg/kg, there was a maximum signiﬁcant
decrease (P< 0.05) of serum PGE-2 compared to using of
M6 mg/kg or T15 mg/kg alone. In M6 mg/kg or T15 mg/kg,
there was signiﬁcant decrease (P< 0.05) of serum PGE-2
compared to control (Table 3).
4. Discussion
In the current study, the combination of tramadol and meloxi-
cam produced a potent anti-nociception effect in the neuro-
pathic pain model in rats. Moreover, our data indicated that,
there is a functional synergistic interaction between tramadol
and meloxicam.
Evidences suggest that nerve injury and immune responses in
injured nerves contribute to the initiation and maintenance of
neuropathic pain that is manifested by hyperalgesia as well as
increase of IL-6 and PGE-2 as pro-inﬂammatory cytokines [23].
Table 3 Mean values ± standard error of serum IL-6 (pg/ml) and PGE-2 (pg/ml) level 5, 10 and 14 days post-operative in chronic
groups.
Treatment IL-6 (pg/ml) PGE-2 (pg/ml)
5 10 14 5 10 14
Saline 540.3 ± 7.2a 403.4 ± 5.8a 260.8 ± 7a 3323.6 ± 57.8a 3297 ± 52.6a 3403.2 ± 12.6a
M6 488.4 ± 13.3a 329.8 ± 10.6a 249.4 ± 16.4a 3309.2 ± 2.7a 2412.2 ± 19.3b 2325.2 ± 37b
T15 459.8 ± 4.5a 319.2 ± 5.7a 244.2 ± 6.8a 3330 ± 298.2a 2765.2 ± 287.3ab 2503.6 ± 285.98ab
T15 +M6 450.6 ± 3.4a 300 ± 6.3a 235 ± 8.2a 3313.8 ± 76.4a 2354.2 ± 1.8b 2139.4 ± 45.9b
Means with different superscript letters at the same column are signiﬁcantly different at P< 0.05.
M6: meloxicam (6 mg/kg).
T15: tramadol (15 mg/kg).
T15 +M6: tramadol (15 mg/kg) and meloxicam (6 mg/kg) combination.
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understood and considered difﬁcult to manage. Neuropathic
pain is a form of chronic pain that arises from functional
changes in the pain sensory system after peripheral nerve in-
jury that is manifested by hyperalgesia and allodynia [24,25].
Thus, in the current study, the using of neuropathic pain rat
model is a major signiﬁcant to understanding of the underlying
mechanism, developing regimen of analgesics and treatment.
Experimental peripheral neuropathy was induced by loose
ligation of rat’s sciatic nerve with chromic gut suture that
was enough to constrict the nerve and retard epineural blood
ﬂow and result in hyperalgesia. The chromic cat gut has an
inﬂammatory response, which lead to the nociceptive hyper-
sensitivity associated with the neuropathic pain model and elic-
its an inﬂammatory response after the tensile strength is lost
that result in increasing activity on the neutral and hot plate
[29]. In this study using of one ligature around the sciatic nerve
with chromic cat gut was sufﬁcient to produce hyperalgesia.
Meloxicam acts through inhibition of PGE-2 synthesis and
its effects were demonstrated in supraspinal analgesia models
[26], while tramadol produces its analgesic effect through inhi-
bition of noradrenaline reuptake [27]. Similarly, in the present
study the synergistic interaction between tramadol and meloxi-
cam in rat after sciatic nerve ligation lead to attenuation of
hyperalgesia. This could be explained by the fact that, trama-
dol increased the ability of meloxicam to inhibit of PGE-2 syn-
thesis via the blockage of cyclooxygenase and the prevention
of cytokines induced hyperalgesia as well as meloxicam
decrease of tramadol doses which is called ‘‘an opioid-sparing
effect’’ [28].
In the acute preemptive groups; hyperalgesia to thermal
stimulations were achieved at maximum severity 2 h after sur-
gery [29]. So the selected time point of 2 h post-operatively was
adequate for the assessment of analgesic drug properties on
neuropathic pain.
In this study, the preemptive saline-treated rats which have
received medetomidine and ketamine as anesthetic combina-
tion showed attenuation of the thermal hyperalgesia within
120–150 min. Medetomidine induced analgesic effect by
decreasing the release of norepinephrine [29] while ketamine
induced analgesia by norketamine (a major metabolite of
ketamine) through binding to the noncompetitive site at the
N-methyl D-aspartate (NMDA)-receptor complex and block-
ing NMDA-mediated central sensitization [30].
Meloxicam is ineffective in enhancing thermal nociceptive
thresholds while it is effective in preventing the developmentof the thermal hyperalgesia as NSAIDs which is able to reduce
the thermal hyperalgesia related to facilitation of spinal neuron
activity [26]. Moreover, tramadol at dose of 15 mg/kg signiﬁ-
cantly attenuated the thermal hyperalgesia resulted from their
peripheral and central effects [27].
In preemptive tramadol and meloxicam group; the with-
drawal latency time had a maximum signiﬁcant reduction com-
pared to control. This might be attributed to the synergism
between tramadol and meloxicam resulting in increased drugs
activity.
On the other hand, the chronic sciatic nerve ligation in rats
lead to exaggerated persistent pain-related behavior, demon-
strated by increased responsiveness to a noxious heat stimulus
‘‘hyperalgesia’’, that was increased 4 days post-operative and
achieved the maximum severity 8 days after surgery. These re-
sult lead to an assumption that, IL-6 is one of most common
cytokines that induces the hyperalgesia [31,32]. Therefore,
analgesics were injected after conﬁrming the development of
thermal hyperalgesia from 5 till 11 days post-operatively to mi-
mic a clinical scenario in which analgesic administration com-
mences only after the manifestation of the symptoms and signs
of painful neuropathic disorders [33]. Also, hyperalgesia ap-
peared 7 days post-operative, which might be due to different
of number of chromic cat gut ligation around sciatic nerve [20].
Tail withdrawal latency time was affected after sciatic nerve
ligation in rats, which could be due to development of second-
ary hyperalgesia to non-injured areas of the body distal to the
injury due to central sensitization (secondary hyperalgesia).
This is because it is not directly associated with the primary in-
jury site [33].
Thermal hyperalgesia in an animal model after chronic
post-operative neuropathy had a signiﬁcant decrease after
chronic systemic administration of tramadol/meloxicam com-
bination at injection days. A micro-opioid agonist therapy sup-
presses thermal hyperalgesia and modulates the nociceptive
input C-ﬁbers responsible for thermal hyperalgesia [34], while
at 12 and 14 days post-surgery thermal hyperalgesia relieves,
which may lead to drug withdrawal syndrome of tramadol
[35].
In the current study, the detection of PGE-2 and IL-6 as a
pro-inﬂammatory cytokines which are an early sensitive bio-
marker for tissue damage, healing process modulation. Both
pro-inﬂammatory cytokines had a role in recognition of cen-
tral nervous system inﬂammation and immune responses,
which are often associated with persistent pain states [36–38].
Consequently; the selection of 2 h for detection of IL-6 and
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ine treatment rats feel thermal stimulations at its maximal
severity during that time.
The preemptive tramadol/meloxicam combination treat-
ment resulted in attenuation of serum IL-6, which could be ex-
plained by the fact that tramadol stimulate the serotonergic
descending inhibitory system resulting in decreased stimulation
of lymphocyte proliferation and decrease of IL-6 production
[14]. In addition, meloxicam had decreased the inﬂammatory
cells production such as immune cells, ﬁbroblasts, endothelial
cells, and neurons which are responsible for IL-6 secretion
after surgical incision [14].
Unlike serum IL-6, serum PGE-2 was signiﬁcantly reduced
by the preemptive or post-operative using of tramadol or
meloxicam alone. The action of NSAIDs meloxicam is based
on the inhibition of cyclooxygenase which converts arachadon-
ic acid into prostaglandins including PGE-2 [27], prostacyclin,
thromboxane and tramadol, which had inhibited noradrenalin
reuptake [27]. Thus, when rats treated with preemptive or
post-operative tramadol/meloxicam combination, it had a
maximum signiﬁcant reduction of PGE-2 than other treatment
[28,39] due to the synergetic interactions between tramadol and
meloxicam.
There was no apparent detectable effect for the systemic
administration of COX inhibitors in animal models for neuro-
pathic pain. However, a pronounced effect has been noticed
with their local administration into the injured nerve itself or
into the hyperalgesic hind paw [8]. The present study proved
that the prolonged administration of meloxicam at 6, 8,
10 days post neuropathic pain, have signiﬁcantly increased
the withdrawal latency time. Consequently, pre- or post-oper-
ative injection of systemic NSAIDs markedly reduced PGE-2
levels, which resulted in a moderate attenuation of thermal
hyperalgesia [17].
In conclusion, the preemptive combination between trama-
dol and meloxicam could be a good choice to overcome the
neuropathic pain by decreasing serum IL-6 level and prevent-
ing PGE-2 release as well as by attenuation of hyperalgesia fol-
lowing sciatic nerve injury.References
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